## Amendments to the Specification:

Please note: to distinguish text passages which were already underlined, additions to the text are marked with <u>double underlines</u>.

Please replace the paragraph at page 9, from line 17 through line 30, with the following paragraph:

--The molecule may be a fusion polypeptide which comprises one or more amino acids interposed between the first and second parts which bind to cells, e.g. a fusion polypeptide which comprises a first amino acid sequence which can bind to an antigen bearing target and a second amino acid sequence which can bind to a leukocyte, and which further comprises at least one amino acid interposed between the first and second parts. The interposed amino acids may comprise, e.g., a linker sequence intended to lessen steric hindrance or other undesirable interactions between the aforementioned first and second parts. For, example, one such type of sequence takes the form (Gly<sub>3</sub>Ser)<sub>n</sub>. Additional useful linkers include, but are not limited to (Arg-Ala-Arg-Asp-Pro-Arg-Val-Pro-Val-Ala-Thr)<sub>1-5</sub> (SEQ ID NO:1) (Xu et al., 1999, Proc. Natl. Acad. Sci. U.S.A. 96: 151-156), (Gly-Ser)<sub>n</sub> (Shao et al., 2000, Bioconjug. Chem. 11: 822-826), (Thr-Ser-Pro)<sub>n</sub> (Kroon et al., 2000, Eur. J. Biochem. 267: 6740-6752), (Gly-Gly-Gly)<sub>n</sub> (Kluczyk et al., 2000, Peptides 21: 1411-1420), and (Glu-Lys)<sub>n</sub> (Klyczyk et al., 2000, supra), wherein n is 1 to 15 (each of the preceding references is also incorporated herein by reference). In another embodiment, no amino acids are interposed between the first and second parts. –

Please replace the paragraph at page 79, from line 14 through line 20, with the following paragraph:

--At the nucleotide level the human and the murine IL4 gene display approximately 70% homology. The 5' region of the IL4 contains several sequence elements, designated CLE (conserved lymphokine element), that are binding sites for transcription factors controlling the expression of this and other genes. A sequence motif, called P sequence (CGAAAATTTCC; SEQ ID NO:1 SEQ ID NO:2) in the 5' region of the human IL4 gene (positions -79 - - 69) is the binding site for a nuclear factor, called NF(P), mediating the response to T-cell activation signals.--

Please replace the line at page 167, line 2, with the following line:

--GTX-5 (SEQ ID NO:3)--

Please replace the line at page 167, line 12, with the following line:

--GTX-6 (SEQ ID NO:4)--

Please replace the line at page 168, line 15, with the following line:

-- Upstream (SEQ ID NO:5)--

Please replace the line at page 168, line 17, with the following line:

-- Downstream (SEQ ID NO:6)--

Please replace the line at page 169, line 14, with the following line:

-- Upstream Primer (SEQ ID NO:7)--

Please replace the line at page 169, line 15, with the following line:

-- Downstream (SEQ ID NO:8) --

Please replace the line at page 170, line 18, with the following line:

--Upstream (SEQ ID NO:9) --

Please replace the line at page 170, line 19, with the following line:

-- Downstream (SEQ ID NO:10) --

Please replace the line at page 178, line 10, with the following line:

-- Upstream (SEQ ID NO:11) --

Please replace the line at page 178, line 12, with the following line:

-- Downstream (SEQ ID NO:12) --

Please replace the paragraph at page 179, from line 13 through line 14, with the following paragraph:

--(SEQ ID NO:13) 5'TACGGCCGGCACCCGCCCGCTCGCCCAGCCCC (SEQ ID NO:14) 3'TACGGCCGCCACAATGAAAATAAGATACCAT --

Please replace the paragraph at page 180, from line 19 through line 20, with the following paragraph:

-- (SEQ ID NO:15) 5' CCGGCACTAGTGGCGGAGGGGGCTCCGGCGGGGGGGGAGCG (SEQ ID NO:16) 5' CTAGCGCTGCCCCCGCCGCCGCCGCCCCCCCCCCCCCCACTAGTG --

Please replace the paragraph at page 180, from line 24 through line 25, and continuing to page 181, lines 1 - 2, with the following paragraph:

Please replace the line at page 181, line 27, with the following line:

-- Upstream HA1 Primer (SEQ ID NO:18) --

Please replace the line at page 182, line 2, with the following line:

-- Downstream HA1 Primer (SEQ ID NO:19) --

Please replace the line at page 182, line 22, with the following line:

-- Upstream Primer (SEO ID NO:20) --

Please replace the line at page 182, line 24, with the following line:

-- Downstream Primer (SEO ID NO:21) --

Please replace the line at page 185, line 11, with the following line:

-- Upstream Primer (SEQ ID NO:22) --

Please replace the line at page 185, line 13, with the following line:

-- Downstream Primer (SEQ ID NO:23) --

Please replace the line at page 186, line 11, with the following line:

-- Upstream Primer (SEQ ID NO:24) --

Please replace the line at page 186, line 13, with the following line:

-- Downstream Primer (SEQ ID NO:25) --

Please replace the line at page 187, line 13, with the following line:

-- Upstream Primer (SEQ ID NO:26) --

Please replace the line at page 187, line 15, with the following line:

-- Downstream Primer (SEO ID NO:27) --

Please replace the line at page 192, line 22, with the following line:

-- Upstream hGM-CSF Primer (SEQ ID NO:28) --

Please replace the line at page 192, line 24, with the following line:

-- Downstream hGM-CSF Primer (SEQ ID NO:29) --

Please replace the line at page 193, line 16, with the following line:

-- Upstream Primer (SEQ ID NO:30) --

Please replace the line at page 193, line 18, with the following line:

-- Downstream Primer (SEO ID NO:31) --

Date: \_\_\_\_3 8 04

Respectfully submitted,

Name: Kathleen Williams

Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP 111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100